The purpose of this study is to evaluate the feasibility of the Mediracer® NCS device in early detection of CIPN in patients receiving potentially neurotoxic substance (vincristine, oxaliplatin or docetaxel) as a part of their chemotherapy regimen.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Nerve conductivity
Timeframe: 6 weeks
Nerve conductivity
Timeframe: 12 weeks
Nerve conductivity
Timeframe: 18 weeks
Nerve conductivity
Timeframe: 24 weeks
Neuropathy related pain
Timeframe: 6 weeks
Neuropathy related pain
Timeframe: 12 weeks
Neuropathy related pain
Timeframe: 18 weeks
Neuropathy related pain
Timeframe: 24 weeks
Chemotherapy induced peripheral neuropathy (CIPN)
Timeframe: 6 weeks
Chemotherapy induced peripheral neuropathy (CIPN)
Timeframe: 12 weeks
Chemotherapy induced peripheral neuropathy (CIPN)
Timeframe: 18 weeks
Chemotherapy induced peripheral neuropathy (CIPN)
Timeframe: 24 weeks
Frequency of CIPN by CTCAE
Timeframe: 6 weeks
Frequency of CIPN by CTCAE
Timeframe: 12 weeks
Frequency of CIPN by CTCAE
Timeframe: 18 weeks
Frequency of CIPN by CTCAE
Timeframe: 24 weeks